Valby, Denmark - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

In connection with the split of Lundbeck's existing shares into A-shares and B-shares completed in June 2022, the Lundbeck Foundation (via its fully owned subsidiary Lundbeckfond Invest A/S)(the Foundation) offered eligible shareholders a 1:1 exchange of their A-shares with the Lundbeck Foundation's B-shares. In accordance with Article 19 of Regulation No. 596/2014 on market abuse, Lundbeck is required to report transactions made by executives and their closely associated parties. This includes the number of shares exchanged.

Following the completion of the exchange offer, the Foundation now holds approximately 80 % of the A-shares and approximately 66 % of the B-shares. The total share capital held by the Foundation is approximately 69 % and the total voting rights held by the Foundation in Lundbeck is approximately 76 %.

Contact:

Investors

Palle Holm Olesen

Vice President

Investor Relations

E: PALO@lundbeck.com

T: +45 30 83 24 26

Media

Juliane Lenzner

Vice President

Corporate Communication

E: JULZ@lundbeck.com

T: +45 36 43 40 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.

(C) 2022 Electronic News Publishing, source ENP Newswire